HIMS · Hims & Hers Health, Inc. · Stock research

Current Thesis

The guide is $680–700M, +25–28% YoY against Q1's $608M and +4%; the street sits at $698.9M revenue and −$0.05 EPS versus +$0.17 a year ago (TipRanks preview). Three things have moved against the frame since the 2026-07-12 note. The FTC, joined by California and Utah, sued in the Northern District of California on 2026-07-29 over health-data sharing with Meta and Snap ad platforms plus undisclosed prescription charges and cancellation friction. The price-target chase reversed — BofA, which raised twice in nine days to $37 on 2026-07-09, has since been marked down to $30 (per analyst-rating aggregators, late July), and the TipRanks consensus target of $30.32 now sits under the $31.59 close of 2026-08-07. And distribution competition arrived on a weekly cadence: Amazon Pharmacy began delivering GLP-1s to eligible Medicare patients at $50/month on 2026-08-06, CVS retooled its weight-management program on 2026-08-05, DarioHealth announced a GLP-1 program on 2026-07-30.

Bullish and bearish views on Hims & Hers Health, Inc.

The model's bull view on Hims & Hers Health, Inc. (HIMS), in brief: The guided inflection is specific and near: Q2 $680–700M (+25–28% YoY) off a $608M/+4% Q1; FY $2.8–3.0B with adj. The bear view: A federal enforcement action with two state AGs attached: filed 2026-07-29 (N.D. Cal.), alleging pixel trackers from Meta, Snap, Microsoft, Pinterest, Reddit and X carried user actions off-site, plus inadequate disclosure of prescription charges and obstructed cancellation. Both cases follow in full.

Bull Case

• The guided inflection is specific and near: Q2 $680–700M (+25–28% YoY) off a $608M/+4% Q1; FY $2.8–3.0B with adj. EBITDA $275–350M, issued with the Q1 print in May 2026. One report settles whether the trough was one quarter or a trend.
• The EPS bar is already negative: consensus −$0.05 against +$0.17 in the year-ago quarter (TipRanks preview). Expectations on profitability have been reset downward ahead of the print; the top line carries the burden.
• Operational basis for the ramp: 125,000+ branded Wegovy shipments in the first six weeks post-launch and roughly 100k+ new weight-loss subscribers per month, per the Q1 2026 call (May 2026).
• Marked insider level: CFO David Wells bought 48,400 shares at $24.23 (~$1.17M) in the open market, Form 4 dated 2026-05-27.
• Funded international platform: the ~$1.15B Eucalyptus acquisition (Australia, UK, Germany, Japan, Canada) closed, backed by the upsized $350M convertible priced in May 2026.
• Tape absorbed the legal headline: the FTC complaint hit 2026-07-29 and shares rebounded on 2026-07-31; the three-month return through 2026-08-07 is +11.7%.
• Product cadence continues: an AI care experience launched 2026-08-06, debuting with Hers Weight Loss members. No revenue contribution has been quantified.

Bear Case

• A federal enforcement action with two state AGs attached: filed 2026-07-29 (N.D. Cal.), alleging pixel trackers from Meta, Snap, Microsoft, Pinterest, Reddit and X carried user actions off-site, plus inadequate disclosure of prescription charges and obstructed cancellation. The subscription-mechanics counts go at the machinery that produces recurring revenue, not at a marketing line. The company called the allegations baseless on 2026-07-29 and said the FTC disregarded evidence supplied across a nearly three-year investigation.
• Distribution is being commoditized by scaled incumbents: Amazon at $50/month for eligible Medicare patients (2026-08-06), CVS's program retool (2026-08-05) on top of its $49 MinuteClinic virtual visit (2026-06-22) and Zepbound coverage (2026-05-28), plus DarioHealth entering (2026-07-30).
• The sell-side re-rating fuel is spent and reversing: Barclays $39 (2026-06-18) and Canaccord $40 (2026-07-01) remain the highs, but BofA's $37 (2026-07-09) has been cut to $30, and the consensus target of $30.32 with a 4 Buy / 8 Hold split sits below spot.
• The quarter before the promise was a miss: Q1 2026 revenue $608M against $616–619M estimates, with roughly $33M of restructuring tied to exiting compounded semaglutide.
• Mechanical overhead near the tape: the $350M convertible converts around $29.53, struck at a 32.5% premium to a $22.29 reference.
• The second narrative leg was capped in July: an analyst flagged the FDA recommendation against adding seven peptides to the bulk list as a limit on the peptide/longevity optionality (2026-07-01).

Setup & Price Structure

Last completed daily close $31.59 on 2026-08-07, 49.7% below the $62.76 52-week high, with RSI(14) at 47.8. Mid-range momentum into a binary print — no thrust, no washout. The $29.53 convertible conversion reference sits immediately beneath spot and is the nearest mechanical level; the $24.23 CFO purchase from 2026-05-27 is the deeper marked floor that held the spring repair.

Narrative life-cycle: SATURATED. The dating is the last ten days. Coverage went fully mainstream on the FTC filing (NPR, CBS News, TechCrunch, Reuters, 2026-07-30). Three competitors announced into the same lane inside eight days (2026-07-30, 2026-08-05, 2026-08-06). And the street's own average target no longer clears the price — $30.32 versus a $31.59 close. That combination of general-audience coverage, incumbent entry and targets at or under spot is late-cycle, and it is a change from the MATURING read carried on 2026-07-12.

Crowding and positioning observables, stated as observables: retail-sentiment coverage is clustering around the print (TipRanks published a retail-sentiment piece on HIMS ahead of Q2 earnings); unusual-options and whale flags recurred on 2026-06-29, 2026-07-06 and 2026-07-08; the earnings date is 2026-08-10, two sessions from the price basis; and the $350M convertible sits ~$29.53 as issuance-linked supply near spot. There is no insider selling in the recent record to point at — the only marked insider action is the May purchase.

Catalyst Calendar (next 30 days)

• 2026-08-10 (confirmed, after close; call 5:00 pm ET) — Q2 2026 results. Resolves the $680–700M guide against a $698.9M consensus that sits at the top of the band.
• 2026-08-10 (same call) — Q3 2026 guidance and the FY $2.8–3.0B / $275–350M adj. EBITDA framework. Whether the reaccel is a quarter or a run-rate is answered here, not in the Q2 number alone.
• ~2026-08-12 (est.) — Q2 10-Q filing. First written contingency language on the FTC action, and the first look at diluted share count against the $29.53 conversion reference.

Elapsed catalysts

• 2026-07-29 (filed; no hearing or response date disclosed as of 2026-08-07) — FTC / California / Utah action, N.D. Cal. Docket milestones are unscheduled, so this is an open-ended overhang rather than a dated event. (passed 2d ago)

What Would Change Our Mind

The cleanest break is arithmetic on 2026-08-10: revenue below the $680M floor of the company's own guide, or a Q3 guide that fails to hold a +25% run-rate, retires the inflection story outright and leaves a business growing in single digits while three scaled incumbents price against it. A second break is legal: a disclosed reserve or a consent order that forces changes to sign-up and cancellation flow would attack subscriber economics directly, and the Q2 10-Q is where that language first appears.

In price terms, a weekly close below $29 loses the $29.53 convertible conversion reference and the pre-print shelf; a subsequent loss of the $24.23 insider-purchase level would break the entire spring repair structure.

The case strengthens on the opposite set: Q2 revenue at or above the $698.9M consensus, the FY $2.8–3.0B band raised rather than reaffirmed, adj. EBITDA tracking inside $275–350M, and a subscriber add that holds the ~100k/month weight-loss pace described on the Q1 call. A ratings upgrade, rather than another target bump, would be the evidence that the sell-side is re-engaging, since targets are already at spot.

Correlation Notes

• GLP-1 supply complex: the branded Wegovy ramp ties the story to Novo Nordisk's supply and pricing decisions; Eli Lilly's Medicare GLP-1 bridge program from 2026-07-01 (announced 2026-06-25) sets the competing access path.
• Retail-distribution read-across: Amazon and CVS announcements now move this name's narrative directly, as seen 2026-08-05 and 2026-08-06.
• Regulatory read-across: the 2026-07-29 FTC theory — ad pixels on health-related pages — applies to any consumer-health platform running third-party trackers, so a settlement here sets a template others get priced against.
• Flow beta over sector beta: the whale/unusual-options clustering of late June and early July means intraday behaviour tracks retail options flow more than healthcare-services indices.
• Low AI-capex linkage: despite the 2026-08-06 AI care launch, this is a consumer-health subscription business; it does not trade with the semiconductor or data-centre complex.